Lumida
/PRCT
⌘K
Procept Biorobotics Corp

Procept Biorobotics Corp

PRCT
$19.22USD↑+0.10%+0.02 today

MARKET CAP

1.1B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$18 – $19

52W RANGE

$18
$62

AI Summary

Stalk
TrimHigh

PRCT remains in a confirmed Stage 4 decline, trading below all declining EMAs with the active Lower Highs & Lower Lows pattern underscoring continuation risk. Medium-term bias is bearish; execution should be deferred until a rally into the declining 9EMA/20EMA zone for rejection at resistance provides a structurally appropriate sell opportunity.

  • ↑Q1 2026 revenue grew 20% YoY to $83.1M on strong U.S. procedure volumes
  • ↑Full-year guidance of $390–410M targets 27–33% growth on 60k–64k procedures
  • ↓Q1 net loss widened to $31.6M from $24.7M YoY, weakening profitability outlook
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Procept Biorobotics Corporation (NASDAQ: PRCT) specializes in robotic-assisted surgical solutions, particularly focusing on aquablation therapy for treating benign prostatic hyperplasia (BPH). As a leading player in the urological sector, Procept aims to capture significant market share within the estimated $4 billion procedural market by leveraging its innovative robotic technology. The current business strategy emphasizes operational efficiency, patient experience enhancement, and expanding clinical applications globally.

Bull says

  • ↑Q1 2026 revenue grew 20% YoY to $83.1M on strong U.S. procedure volumes
  • ↑Full-year guidance of $390–410M targets 27–33% growth on 60k–64k procedures
  • ↑Q1 gross margin held at 65%, reflecting pricing discipline and operational efficiency
  • ↑Cash balance of $249M supports expansion and 210 robotic system placements in 2025
  • ↑International rollout, notably in the UK, offers additional revenue diversification
  • ↑Analyst consensus price target of $30.29 suggests ~47% upside potential

Bear says

  • ↓Q1 net loss widened to $31.6M from $24.7M YoY, weakening profitability outlook
  • ↓Operating expenses jumped to $74M in Q2 2025, risking further margin compression
  • ↓Elevated leverage and size risk could strain liquidity amid market shifts
  • ↓Competitive threats from PAE alternatives and incumbents like ISRG may erode market share
  • ↓Tight hospital capex decisions could delay new system sales
  • ↓Weak profitability factors and high leverage risk highlight balance sheet strain

Investment themes with PRCT

Medical Devices↑ +0.12%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-01-2026neutral

Transcript signals

Bull points

  • We are encouraged by our Q1 results and the momentum we are building, having reported total revenue of $83.1 million, representing an annual growth of 20%.
  • we believe field inventory levels and customer purchasing behavior have normalized, with handpieces sold representing approximately 95% of procedures in the first quarter.
  • We remain confident in our full-year system plan and are encouraged by the early positive customer response to the AquaBeam replacement program.

Bear points

  • procedures were a little light of the street and grew 31%
  • the midpoint of $93 million is a little below the street at $95 million.
  • Net loss for the first quarter of 2026 was $31.6 million, compared to a net loss of $24.7 million in the first quarter of 2025.
Read full transcript analysis ›